Part B Insider (Multispecialty) Coding Alert
Stable Angina Patients Could Soon Have Access To ECP Therapy
PDF
And one carrier medical director weighs in for tumor assay
If you've got something to say about Medicare coverage of External Counterpulsation (ECP) therapy or Immunoassay CA-125, now's your chance to share your thoughts with the nation.
The Centers for Medicare and Medicaid Services just started accepting comments on both of those issues, and you can comment by going to www.cms.hhs.gov/coverage and clicking on "tracking sheets."
The Food and Drug Administration approved using ECP devices for treating patients with unstable and stable angina pectoris, acute myocardial infarction, congestive heart failure and cardiogenic shock as an alternative to surgery or angioplasty. CMS currently covers uses for patients diagnosed with inoperable, disabling angina who are risky candidates for surgery.
Westbury, NY-based Vasomedical, Inc. asked CMS to consider expanding ECP coverage to patients with Class II angina and New York Heart Association Class II/III stable heart failure symptoms within an ejection fraction less than or equal to 35 percent.
Commenters urged CMS to go even further in covering ECP. Heart failure patients who continue to have symptoms after optimal medical therapy need ECP because they don't have a lot of other options, according to comments submitted by Minneapolis, MN cardiologist Bradley Bart. "ECP is an incredibly effective treatment for both heart failure and angina," writes Beverly Hills, CA cardiologist Norman Lepor.
Meanwhile, CMS also is considering whether to cover the CA-125 immunoassay for primary peritoneal adenocarcinoma, which follows a path similar to epithelial ovarian cancer. CMS already covers CA-125 for ovarian carcinoma.
"These tumors are treated like ovarian cancer," Charlotte, NC OB-Gyn Robert Higgins says in early comments. "Following CA-125 levels during their therapy is helpful in determining their response to chemotherapy," and also can help track patients who appear to be in remission.
One early commenter on this issue may carry some extra influence: Alton Wagnon, carrier medical director with Regence Blue Cross/Blue Shield of Utah, was a practicing oncologist for 25 years and notes that the CA-125 test was useful in tracking primary peritoneal carcinoma.
Part B Insider (Multispecialty) Coding Alert
- CHEMOTHERAPY PAYMENTS:
Drug Payments For These Commonly Prescribed Drugs Drop Up To 38 Percent In July
Overall drug payments face 2 percent cut
If oncologists were hoping for a break from third-quarter [...] - PAY FOR PERFORMANCE:
AMA Will Oppose Any P4P That Doesn't Meet Standards
And that includes proposals now before Congress
Pay-For-Performance (P4P) anxiety dominated the American Medical Association's House [...] - COVERAGE:
Stable Angina Patients Could Soon Have Access To ECP Therapy
And one carrier medical director weighs in for tumor assay
If you've got something to say [...] - New Drug Payment Levels:
Top Chemotherapy Winners and Losers - MODIFIERS:
AMA Plans Modifier 25 Clarification
Plus: Modifiers 58 and 78 on the slate for clarification
When a patient comes in with [...] - CRITICAL CARE:
Two Physicians, One Hour-Who Bills For Critical Care?
With many hospitals hiring critical care teams to handle critical cases, physicians are finding themselves [...] - CMS Monitoring IVIG Access/Majority Og Chiropractic Claims Have Documentation Problems
CMS Monitoring IVIG Access
Some advocacy groups and providers have complained that patients are having trouble [...] - Part B Coding Coach:
Avoid V Codes And Risk Vaporizing Valuable Green
Fact: V codes can verify medical necessity and validate higher E/M levels
Coders often shun V [...] - Forget These Screening Codes And Forget Payment From CMS
V codes play a vital role in Medicare's screening services - and failure to use [...] - PHYSICIAN NOTES:
Information Technology May Be Available Soon
Two bills would standardize IT, provide grants
For your information, the government may soon be helping [...]